ElevateBio Archives - Medical Design Sourcing

50 of the best-funded biotechs of 2023

[Adobe Stock]

As the year draws to a close, it is clear that molecular science and diagnostics is the hottest funding area in the biotech industry. In an analysis of 50 of the best-funded biotechs of 2023 focused on human health, molecular and science and diagnostics startups collectively attracting roughly $945 million, dwarfing the figures in other segments. The next popular two niches, gene therapies and oncology, had average funding levels of approximately $245 million and $170 million, respectively. While AI has received a significant amount of attention this year, biotechs specializing in that field garnered an average funding of only about $66 million. Outside of the life sciences, startups with a broader focus on AI raised a cumulative average of $202.47 million, based on an analysis of close to 1000 companies.

Caris Life Sciences has raised nearly $1.7B to date

In terms of best-funded companies overall,…

100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.

B…

Surgical robotic developer leads device makers in top healthcare VC deals

CMR Surgical’s Versius system console [Photo courtesy CMR Surgical]

Surgical robotics developer CMR Surgical was the lone medical device maker in the 10 largest healthcare venture capital deals of 2021 in the U.S. and Europe.

That’s according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB), which recently published its annual VC analysis drawing on its own proprietary information and data from Pitchbook.

Cambridge, U.K.–based CMR Surgical raised $600 million in a Series D financing round announced in June. CMR’s Versius surgical robotic system is available in Europe, Australia, India and the Middle East, but has not been approved by the FDA.

CMR Surgical today announced its expansion into Poland as a hub for Central and Eastern Europe, and last week said its robotic system has been used in thoracic surgery, specifically oesophagomyotomies, lobectomies a…

Boston Children’s Hospital, ElevateBio enter 5-year cell, gene therapy collaboration

Boston Children’s Hospital announced today that it partnered with ElevateBio for a five-year cell and gene therapy advancement program.

The collaborative agreement will seek to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.

Get the full story at our sister site, Drug Delivery Business News.